Join
Live feed
·
PRReleasevia Quantisnow
Seres Therapeutics Inc. logo

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

ByQuantisnow·Wall Street's wire, on your screen.
MCRB· Seres Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MCRB (Seres Therapeutics Inc.) and more on Quantisnow.